Wegovy vs Zepbound: A Comparison of Two FDA-Approved Weight Loss Medications

A common question patients ask about Wegovy and Zepbound is how their weight-management effects differ. Both have been studied in large clinical programs, and individual results always vary.

Wegovy contains semaglutide and was evaluated in a clinical trial program in adults with obesity or overweight, with treatment given alongside lifestyle intervention. The studies established it as an FDA-approved option for chronic weight management.

Zepbound contains tirzepatide and was studied in its own clinical trial program in adults across several dose levels. The studies established it as an FDA-approved option for chronic weight management.

No trial has directly compared the two at their respective maximum doses. The two medications differ in mechanism — semaglutide acts on the GLP-1 pathway, while tirzepatide acts on both the GIP and GLP-1 pathways — and a clinician can help determine which approach fits a given patient. Any GLP-1-based treatment should be prescribed and monitored by a licensed provider.

The difference in outcomes seen between Zepbound and Wegovy stems in part from their distinct receptor mechanisms. Understanding the pharmacological differences helps explain why these two medications, both given as weekly injections, can produce different outcomes.

Wegovy contains semaglutide, which acts exclusively on GLP-1 receptors. This single-receptor approach produces powerful appetite suppression, slowed gastric emptying, and improved insulin dynamics. The STEP trial program demonstrated that these effects, while targeting only one hormonal pathway, are sufficient to produce clinically significant weight loss in most patients.

Zepbound contains tirzepatide, which simultaneously activates both GIP and GLP-1 receptors. The GIP component adds metabolic effects that complement and amplify the GLP-1 pathway. GIP receptor activation improves insulin sensitivity in fat tissue, enhances lipid metabolism, and may provide additional appetite-regulating signals in the brain that operate through different neurological circuits than GLP-1.

Emerging research suggests the dual mechanism may also produce differences in body composition. Preliminary analyses from SURMOUNT trials indicate that tirzepatide patients may preserve a slightly higher proportion of lean muscle mass relative to fat mass during weight loss. This is a critical consideration, as muscle loss during rapid weight reduction can negatively impact metabolic rate, functional capacity, and long-term weight maintenance.

Weight loss medications are increasingly evaluated not just for pounds lost, but for their impact on cardiovascular disease — the leading cause of death in patients with obesity. In this arena, Wegovy currently holds a significant evidence advantage.

The SELECT trial, published in 2023, was a landmark cardiovascular outcomes study for semaglutide. Over 17,600 adults with overweight or obesity and established cardiovascular disease (but without diabetes) were randomized to semaglutide 2.4 mg or placebo. Semaglutide reduced the risk of major adverse cardiovascular events (MACE — cardiovascular death, nonfatal heart attack, or nonfatal stroke) by 20% over a median follow-up of 33 months. This led to an expanded FDA indication for Wegovy for cardiovascular risk reduction in March 2024.

Zepbound does not yet have dedicated cardiovascular outcomes data. Eli Lilly's SURPASS-CVOT trial evaluating tirzepatide's cardiovascular effects is ongoing, with results expected in the coming years. However, tirzepatide's metabolic effects — substantial reductions in body weight, blood pressure (6-9 mmHg systolic), triglycerides (19-25%), and inflammatory markers — suggest a favorable cardiovascular profile.

Additionally, Wegovy demonstrated benefits in heart failure. The STEP-HFpEF trial showed that semaglutide significantly improved symptoms, physical limitations, and exercise function in obese patients with heart failure with preserved ejection fraction (HFpEF), a condition with limited treatment options.

Both Wegovy and Zepbound cause gastrointestinal side effects as their primary adverse reactions. These effects are inherent to incretin-based therapies and are generally most pronounced during dose escalation.

Clinical data for Wegovy showed gastrointestinal effects were the most common adverse reactions — nausea, diarrhea, vomiting, constipation, and abdominal pain. The relatively high incidence of nausea and vomiting is notable, though these effects are typically transient and most common during the dose-escalation phase. A small share of participants discontinued treatment due to adverse events.

Clinical data for Zepbound showed generally lower gastrointestinal effect rates — nausea, diarrhea, vomiting, constipation, and decreased appetite — with discontinuation due to adverse events also affecting a small share of participants. The lower nausea and vomiting rates are potentially significant for patients who are particularly sensitive to GI disturbances.

Both medications share class-wide safety considerations: boxed warnings for medullary thyroid carcinoma risk (based on rodent studies), contraindication in patients with MEN 2 syndrome, and warnings regarding pancreatitis and gallbladder disease. Acute kidney injury has been reported rarely with both, typically in the context of severe dehydration from GI side effects.

For patients pursuing weight loss without diabetes, cost is often a major consideration when discussing Wegovy® and Zepbound® — especially since insurance coverage for anti-obesity medications remains inconsistent.

Novo Nordisk has offered Wegovy® savings programs, but supply constraints have periodically limited availability, and insurance coverage has improved yet is far from universal. As of 2025, roughly 40-50% of commercial plans offer some coverage for anti-obesity medications, though prior authorization requirements, step therapy, and quantity limits are common. Medicare coverage for weight loss drugs expanded in 2026 following legislative action.

Eli Lilly has been aggressive with Zepbound® patient access programs, including a direct-to-consumer cash-pay option through LillyDirect. Insurance coverage patterns for Zepbound® are similar to Wegovy®, with the added complexity that it launched more recently and may not yet be on all formularies. For patients without coverage, brand-name pricing is frequently cited as a barrier.

Weight Method offers a separate path: a compounded-medication program through licensed compounding pharmacies, with predictable flat pricing instead of insurance variability. Compounded semaglutide is available at $154 per month, and compounded tirzepatide at $329 per month — an all-inclusive subscription covering clinician evaluation, personalized dosing, and ongoing medical oversight, with no prior authorizations or pharmacy runs. Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality.